Nivolumab as first-line treatment in non-small cell lung cancer patients-key factors: tumor mutation burden and PD-L1 ≥50%

被引：10

作者：

Zarogoulidis, Paul ^{[1
]}

Papadopoulos, Vasilis ^{[2
]}

Maragouli, Elena ^{[2
]}

Papatsibas, George ^{[2
]}

Sardeli, Chrysanthi ^{[3
]}

Man, Yan-Gao ^{[4
]}

Bai, Chong ^{[5
]}

Huang, Haidong ^{[5
]}

机构：

[1] Theageneio Canc Hosp, Pulm Dept, Oncol Unit, Thessaloniki, Greece

[2] Univ Thessaly, Dept Oncol, Larisa, Greece

[3] Aristotle Univ Thessaloniki, Fac Hlth Sci, Sch Med, Dept Pharmacol & Clin Pharmacol, Thessaloniki, Greece

[4] Vet Affair Hlth Syst, Lab Prote & Prot Sci, Baltimore, MD USA

[5] Second Mil Med Univ, Changhai Hosp, Dept Resp & Crit Care Med, Shanghai 200000, Peoples R China

来源：

TRANSLATIONAL LUNG CANCER RESEARCH | 2018年 / 7卷

关键词：

SMALL BIOPSY; CASE SERIES; STAGE IV; EXPRESSION; SPECIMENS; THERAPY; SAMPLES; UPDATE;

D O I：

10.21037/tlcr.2018.01.04

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S28 / S30

页数：3

共 50 条

[1] Outcomes to first-line pembrolizumab in patients with non-small cell lung cancer and a PD-L1 tumor proportion score ≥90%.
Aguilar, Elizabeth Jimenez
Ricciuti, Biagio
Gainor, Justin F.
Nishino, Mizuki
Adeni, Anika E.
Subegdjo, Safiya
Khosrowjerdi, Sara
Peterson, Rachel
Digumarthy, Subba
Liu, Corinne
Sauter, Jennifer L.
Rizvi, Hira
Arbour, Kathryn Cecilia
Carter, Brett W.
Heymach, John
Altan, Mehmet
Hellmann, Matthew David
Awad, Mark M.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[2] Increased Tumor Mutation Burden Levels and Sensitivity of Non-Small Cell Lung Cancer to PD-L1 Blockade
Aslan, Volkan
Yazici, Ozan
Ozdemir, Nuriye
JAMA ONCOLOGY, 2023, 9 (04) : 570 - 570
[3] First-line treatment options for advanced non-small cell lung cancer patients with PD-L1 ≥ 50%: a systematic review and network meta-analysis
He, Mingfeng
Zheng, Taihao
Zhang, Xiaoyue
Peng, Yuan
Jiang, Xuan
Huang, Yusheng
Tan, Benxu
Yang, Zhenzhou
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (06) : 1345 - 1355
[4] First-line treatment options for advanced non-small cell lung cancer patients with PD-L1 ≥ 50%: a systematic review and network meta-analysis
Mingfeng He
Taihao Zheng
Xiaoyue Zhang
Yuan Peng
Xuan Jiang
Yusheng Huang
Benxu Tan
Zhenzhou Yang
Cancer Immunology, Immunotherapy, 2022, 71 : 1345 - 1355
[5] Nivolumab beyond First-Line (1L) Treatment in Metastatic Non-Small Cell Lung Cancer (NSCLC)
Sotelo, Miguel
Chara, Luis
Riquelme, Alejandro
Toro, Piedad
Lopez, Cynthia
Hernando, Susana
Caviedes, Edinson
Aguayo, Cristina
Bueno, Coralia
Mielgo Rubio, Xabier
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1340 - S1341
[6] Tumor Mutation Burden as a Potential Biomarker for PD-1/PD-L1 Inhibition in Advanced Non-small Cell Lung Cancer
Di Huang
Fan Zhang
Haitao Tao
Sujie Zhang
Junxun Ma
Jinliang Wang
Zhefeng Liu
Pengfei Cui
Shixue Chen
Ziwei Huang
Zhaozhen Wu
Lei Zhao
Yi Hu
Targeted Oncology, 2020, 15 : 93 - 100
[7] Tumor Mutation Burden as a Potential Biomarker for PD-1/PD-L1 Inhibition in Advanced Non-small Cell Lung Cancer
Huang, Di
Zhang, Fan
Tao, Haitao
Zhang, Sujie
Ma, Junxun
Wang, Jinliang
Liu, Zhefeng
Cui, Pengfei
Chen, Shixue
Huang, Ziwei
Wu, Zhaozhen
Zhao, Lei
Hu, Yi
TARGETED ONCOLOGY, 2020, 15 (01) : 93 - 100
[8] Integration of Tumor Mutation Burden and PD-L1 Testing in Routine Laboratory Diagnostics in Non-Small Cell Lung Cancer
Schatz, Stefanie
Falk, Markus
Jori, Balazs
Ramdani, Hayat O.
Schmidt, Stefanie
Willing, Eva-Maria
Menon, Roopika
Groen, Harry J. M.
Diehl, Linda
Kroeger, Matthias
Wesseler, Claas
Griesinger, Frank
Hoffknecht, Petra
Tiemann, Markus
Heukamp, Lukas C.
CANCERS, 2020, 12 (06) : 1 - 14
[9] The impact of genomic mutational status on PD-L1 expression and tumor mutation burden in non-small cell lung cancer
Zhou, Qing
Gu, Weiguang
Fu, WenFan
Mai, Shijie
Lin, Daren
Zhang, Shiyue
Wang, Wenjing
Zhang, Peng
CANCER RESEARCH, 2019, 79 (13)
[10] PD-L1 inhibitors as monotherapy for the first-line treatment of non-small cell lung cancer in PD-L1 positive patients: A safety data network meta-analysis
Garcia Campelo, M. R.
Arriola Aperribay, E.
Campos Balea, B.
Lopez-Brea, M.
Fuentes Pradera, J.
de Castro Carpeno, J.
Aguado, C.
Perez Parente, D.
de Oro-Pulido, F.
Rodriguez Abreu, D.
ANNALS OF ONCOLOGY, 2021, 32 : S1413 - S1414

← 1 2 3 4 5 →